BioMarin's resources did not go unnoticed by ... compared to Voxzogo's once-a-day doses. Meanwhile, Japanese pharma Otsuka recently picked up a clinical-stage PKU asset from Jnana Therapeutics ...

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President; Biomarin Pharmaceutical Inc Cristin ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...